Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Phase 1/2 Completed 31 enrolled M.D. Anderson Cancer Center Bristol-Myers Squibb · collab

NaSequentialOpen-labelTreatment

Summary

The goal of this clinical research study is to find the highest tolerable dose of dasatinib and Zometa (zoledronic acid) that can be given in combination for the treatment of breast cancer that has spread to the bone. The safety and effectiveness of this combination will also be studied.

Timeline

Start: 2007-11-01
Primary completion: 2020-11-17
Completion: 2020-11-17

Publications

Chen F, Zhao B, Tian Y, Liu Q, Zhang B. Metabolic reprogramming on breast cancer stem Cells: Proliferation and self-renewal, epithelial-mesenchymal transition (EMT), and drug resistance. Biochem Biophys Res Commun. 2025 Aug 8;774:152079. doi: 10.1016/j.bbrc.2025.152079. Epub 2025 May 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zoledronic acid	Other / unclassified	4 mg	Intravenous
Subject	dasatinib anhydrous	Small molecule	100 mg	Oral

Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Summary

Timeline

Publications

Drugs

Indications